Västra Hamnen Corporate Finance Initiates Coverage of ViroGates
ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test products, primarily for emergency departments in hospitals, today announces that Västra Hamnen Corporate Finance AB will initiate research coverage of ViroGates.
The research coverage is governed by an agreement made between ViroGates and Västra Hamnen Corporate Finance. The analysis comprises an independent review of the Company, its products, markets and competitors as well as a financial scenario that constitutes the basis of an estimated justified market capitalization of ViroGates.
In its initiation coverage report, Västra Hamnen Corporate Finance AB concludes:
“Our DCF model suggests a fair value range for the stock price of DKK 68.00 – DKK 100.50 given our current view of the risk and including only the Acute Care market in our model. We see potential for further valuation upgrades when the company has overcome certain risks and when it gets closer to addressing other market segments.”
For additional information, please contact
CEO Jakob Knudsen
Tel. (+45) 2226 1355, Email:firstname.lastname@example.org
ViroGates A/S - www.virogates.com
Västra Hamnen Corporate Finance
Tel. (+46) 40 200 250, Email:email@example.com
Information om ViroGates
ViroGates is an international medtech company developing and marketing prognostics products to improve patient care, reduce healthcare costs and empower clinical staff in the healthcare sector. Based on more than 600 clinical trials and studies, ViroGates’ suPARnostic® product range supports hospital professionals in making clinical decisions on hospitalization or discharge of acute care patients as well as detecting and assessing the severity of cardiovascular diseases, type 2 diabetes, cancer, etc. suPARnostic® TurbiLatex is available on Roche Diagnostics’ Cobas instruments and ViroGates works with partners to develop solutions for other platforms. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Germany, Spain, and France, while distributors serve other markets. www.virogates.com
Følg pressemeddelelser fra ViroGates
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra ViroGates
ViroGates announces initial data on the use of suPARnostic® in the triaging of patients with COVID-19 symptoms1.5.2020 12:03:01 CEST | Pressemeddelelse
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that clinical researchers from the US, Greece and Denmark have disclosed the first clinical data on suPAR in patients affected by the novel coronavirus SARS-CoV-2.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum